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Abstract 
Atherosclerosis is a chronic arterial disease which impacts systemically the function of 
organs and tissues by causing inflammation and disruption of blood supply. During 
atherogenesis, lipid deposits, inflammation, and cells accumulate within the walls of arteries, 
ultimately leading to a buildup of fatty plaques and occlusion of the arterial lumen.  In a 
multifactorial disease like atherosclerosis there are complex interplays between 
environmental, genetic and epigenetic risk factors. The epigenetics of atherosclerosis 
involving DNA methylation has been progressing from single gene to genome wide 
analyses. Although these epistudies have provided evidence that DNA methylation exists 
within certain genes during atherogenesis, the presence and effects of DNA methylation and 
hydroxymethylation are not fully understood and their impact on vascular cell signal 
transduction and proliferation may prove to be critically important. 
Hypothesis and Aims. The central hypothesis of this project is that an imbalance between 
DNA methylation and demethylation occurs in the lesions of atherosclerosis, which leads to 
changes in vascular gene expression, in particular those coding for growth factor receptors. 
The long term goal of this research is to elucidate the epigenetic mechanisms, mainly DNA 
methylation and hydroxymethylation, and their contribution to the progression or 
reprogression of atherogenesis. 
The specific aims are to use in vitro and in vivo models of atherosclerosis to examine the 
functional role of, and the mechanisms contributing to, DNA methylation and 
hydroxymethylation in  insulin-like growth factor 1 receptor (IGF-1R) expression during 
atherogenesis triggered by genetic knockout of ApoE and/or the addition of high fat.  
Methods and Results. Atherosclerosis is a chronic arterial disease systemically impacting 
the function of organs and tissues by causing inflammation and disruption of blood supply. 
The presence and effects of DNA methylation and hydroxymethylation during atherogenesis 
are not fully understood and their impact on vascular cell signal transduction and 
proliferation may prove to be critically important. Here we seek to examine the functional 
role of DNA methylation and hydroxymethylation in  insulin-like growth factor 1 receptor 
(IGF-1R) expression during atherogenesis triggered by genetic knockout of ApoE and/or the 
addition of high fat. Using cultured vascular smooth muscle cells (VSMCs) and murine 
models of atherosclerosis, high fat diet feeding augments the inhibitory effect of ApoE 
  VII 
deficiency on DNA methylation and hydroxymethylation in the aortas with severe plaques. 
Interestingly, the same induction of atherosclerosis causes a decrease in hydroxymethylation 
but an increase in methylation within the promoter region of the IGF-1R gene. Results detail 
the identification of TET2 as an epigenetic regulator that acts upstream of IGF-1R during 
atherogenesis through demethylation of the promoter area. We further show that TET2 
mRNA and protein were found to be regulated by the mTORC1 signaling pathway, and 
selective rapamycin-induced inhibition of mTOR can reactivate IGF-1R expression through 
up-regulation of TET2 and hydroxymethylation of the IGF-1R promotor. 
Conclusion. Identification of  altered DNA methylation/hydroxymethylation in the arterial 
wall during atherosclerosis and its contribution to the down-regulation of IGF-1R during 
atherosclerosis may lend itself to altering key components of the mTOR-TET2-5-hmC 
pathway and thereby lead to novel therapeutic targets for treating disease. 
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Chapter 1: Introduction  
 
 
 
 
Motivation for Atherosclerosis Research 
 
 Cardiovascular disease (CVD) is a complex multifactorial designation for disorders 
of the heart and vascular system consisting of heart disease, stroke, other vascular diseases. 
According to recent data from the Centers for Disease Control (CDC), CVD is the leading 
cause of death within the United States, accounting for roughly 1 in every 3 deaths annually.  
An estimated 85.6 million adults suffer from CVD in the United States according to the 
2015 statistic from the American Heart Association (AHA)  (Mozaffarian, Benjamin et al. 
2015).  Moreover, CVD is the leading cause of death globally resulting in 17.3 million 
deaths or 32% in 2014 and becoming more and more prevalent in developing countries 
(2015). 
 As the prevalence continues to increase throughout the world, CVD rates are slowly 
declining within the United States.  For instance, from 2001 to 2011, death rates attributable 
to CVD declined 30.8% and the actual number of CVD deaths per year declined by 15.5%. 
Although significant progress is being made to decrease the rate and overall deaths, in 2011, 
CVD still accounted for 31.3% (786,641) of all 2,515,458 deaths, or approximately 1 of 
every 3 deaths in the United States. On the basis of the 2011 death rate data,  more than 
2,150 Americans die of CVD each day, an average of 1 death every 40 seconds. 
Approximately 155,000 Americans who died of CVD in 2011 were younger than 65 years of 
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age and 34% of deaths attributable to CVD occurred before the age of 75 years, which is 
younger than the current average life expectancy of 78.7 years (Mozaffarian, Benjamin et al. 
2015).   
 Along with the mortality caused by CVD, the morbidity associated with CVD can 
have a profound impact not only on a person's capacity to do their job, but also, their 
capability to work at all. Because of the nature of the disease and the symptoms related to it, 
the complete economic cost associated with the loss of work due to CVD is difficult to 
calculate. However, it is estimated that the total occupational and economic cost from CVD, 
including heart disease, stroke, and high blood pressure, accounts for more economic loss 
than any other disability, disease, or injury (Price 2004). 
 As the current statistics show, although progress is being made to decrease the death 
rate and overall mortality and morbidity, CVD and its underlying conditions remain the 
most significant disease challenge faced today. That being said, improved prognoses can be 
attributed, in part, to new therapies and interventions, as well as a better understating of the 
basic science underlying the disease.  
 
Overview of Atherosclerosis 
 
 The underlying mechanisms of CVD vary depending on the subtype of disease, but a 
atherosclerosis is a major contributing factor. Atherosclerosis is a systemic disease process 
in which lipid deposits, inflammation, cells, and scar tissue build up within the walls of 
arteries, ultimately leading to a buildup of fatty plaques and occlusion of the arterial wall. 
This accumulation and occlusion, as well as the rupture and dislocation of the plaques,  
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contributes to a large number of cardiovascular incidents. Atherosclerosis is a systemic 
disease and blood vessels susceptible to atherosclerosis supply the heart, kidneys, brain, as 
well as every other organ in the body. However, the degree and susceptibility of 
atherosclerosis varies between patients and may produce different effects in the size of the 
plaque area and the vessels and locations.  
 
Cellular Components of Atherosclerosis 
 
 Atherosclerosis is a disease originating within arteries. The arteries are vessels 
primarily responsible for the transportation of blood from the heart throughout the 
circulatory system. The artery is a tubular structure consisting of three distinct layers, the 
tunica adventitia or externa, tunica media, and tunica intima, which are separated by an 
internal and external elastic membrane. The layer closest to the lumen of the artery is the 
tunica intima which contains a single layer of endothelial cells (EC) arranged in a 
cobblestone-like morphology. ECs line the vessel and are involved in several functions 
as they come in contact with blood, such as, providing an anti-thrombogeneic effect, 
hormone, nutrient, and cytokine trafficking, and neutrophil recruitment. The tunica 
media, separated from the tunica intima by layers of elastin, makes up the majority of the 
artery and consists primarily of vascular smooth muscle cells (VSMC). VSMCs are 
arranged in concentric layers of cells interlaced with a matrix consisting of collagen, 
elastin, and proteoglycans. VSMCs contain three types of adrenergic receptors, α1,α2, and 
β2. These receptors act to regulate muscle tone and provide a vascular response to various 
stimuli within the artery through vasoconstriction and dilation. Surrounding the tunica 
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media and separated by a external elastic membrane is the tunica adventitia. The tunica 
adventitia consists of a loose connective tissue layer containing collagen and permeated 
with by blood vessels. These blood vessels, named vasa vasorum, serve to provide 
nutrients and oxygen to the metabolically active medial layer. As the arteries progress 
further from the heart, they bifurcate and branch out, forming progressively smaller 
vessels with smaller, less dense, tunica medial layers as they progress from arterioles to 
capillaries.  
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Figure 1. Gross anatomical structure of the artery. 
Diagram of a large artery and the major contributing layers.  The artery consists of three 
main layers, the adventitia, media, and intima, and their contributing cellular and non-
cellular components.  
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Pathogenesis of Atherosclerosis 
 Atherosclerosis is the thickening of the arterial wall in a process caused by 
inflammation, cellular migration and cellular dysfunction. The formation of atherosclerosis 
begins with an initial lesion, which, although morphologically "normal",  is characterized by 
macrophage infiltration and isolated foam cells, which are macrophages laden with low-
density lipoproteins (LDLs), as well as other lipids. As the lesion progresses, the formation 
of a fatty streak arises, which is distinguished by greater numbers of foam cells beneath the 
endothelium and by intracellular lipid accumulation (Rader and Daugherty 2008).  
 
 As atherosclerosis progresses, an intermediate lesion followed by an atheroma is 
formed.  This process is marked by greater intracellular lipid accumulation and extracellular 
lipid pooling, as well as VSMCs infiltrating and proliferating within the lesion.  VSMCs 
produce extracellular matrices made up primarily of collagen, which leads to greater 
amounts of extracellular lipid pooling and the formation of extracellular lipid cores. As the 
atheroma develops, chronic inflammation drives an immune response which leads to 
recruitment of T cells to the atherosclerotic plaque. During the transition from atheroma to a 
fibroatheroma, VSMCs continue to increase and a fibrous cap is formed through the 
entrapment of cholesterol and other cellular debris in and around the endothelial cell layer. It 
is also during this time that lipid cores accumulate and cells become necrotic, releasing 
crystalline cholesterol that can lead to calcification. As this occurs, atherosclerosis 
transitions from clinically silent to clinically overt and contributes to clinical symptoms of 
atherosclerosis. When surface deficits become present within the fibrotic cap, the plaque 
becomes a complicated lesion. This type of plaque tissue can completely occlude vessels 
and, due to surface deficits and instability, is rupture prone which can cause thromboses and 
ultimately lead to stroke or MI.   
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Figure 2. Cellular components of an atherosclerotic plaque. 
During the process of atherogenesis, plaque tissue is marked by cellular migration and 
dysfunction triggered by inflammation. Cellular recruitment of  lymphocytes, specifically 
CD4+ T helper 1 (Th1) and natural killer T (NKT) cells, occurs as an immune response and 
to clear glycolipid antigens. Migration of macrophages within the plaque to clear cellular 
debris and lipid accumulation creates pro-atherogenic foam cells. As the severity of the 
plaque progresses, migration and proliferation of VSMC causes medial thickening. During 
late stages, the plaque undergoes endothelial damage and dysfunction, causing the formation 
of a fibrous cap, which ultimately, leads to instability and plaque rupture. 
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Complications from Atherosclerosis 
  
 The process of atherosclerosis progression typically occurs over a decades-long 
period of time.  During the early stages of atherosclerosis, the effects are often clinically 
silent. Nevertheless, as the endothelium erodes and becomes damaged, there is the 
possibility that the formation of thrombi can occur quickly. This sudden formation of a 
thrombus often results in the total occlusion of the vessel. However, more frequently the 
endothelium will remain intact, causing the artery to compensate as the atherosclerotic 
plaque transitions from an intermediate lesion to an atheroma. As this occurs, the artery 
can dilate and maintain the approximate luminal dimensions until the atheroma reaches 
around 35-40% occlusion. At this time the lumen will become increasingly narrow, 
impeding the blood flow rate and frequently, as a compensatory mechanism, elevating 
blood pressure. The atherosclerotic plaque typically does not enlarge at a constant rate, 
but rather in short segments. This may be accounted for by the disruption of micro-
vessels that supply nutrients to the VSMCs within the tunica media.  
 As these vessels become damaged due to inflammation, they can cause intra-
plaque hemorrhage, which in turn, can stimulate VSMC recruitment and proliferation 
(Dutta, Courties et al. 2012). During this process, where arterial occlusion worsens, the 
clinical manifestations change from clinically silent to overt and include a host of 
complications, including unstable angina pectoris, peripheral artery disease, and ischemic 
stroke. As the fibrous cap of a complicated lesion ruptures, this results in the release of 
inflammatory cytokines and coagulation factors into the circulating blood and around the 
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proximity of the plaque. The result is rapid clot formation that has been shown to account 
for roughly 75% of  acute myocardial infarctions (Libby 2002).       
 
Risk Factors  
 
 During the late 1940's, scientists and a group of recruited patients embarked on an 
ambitious project to identify contributing causes of cardiovascular disease in what was 
termed the Framingham Study (Dawber, Meadors et al. 1951).  The term "risk factor" was 
introduced into medical terminology during the course of the study to describe the causes of 
pathophysiological events; the modifications of which could significantly decrease the 
likelihood of adverse cardiovascular and cerebrovascular events (Dawber, Kannel et al. 
1959). Since the Framinham Study, many more studies have been conducted to illuminate 
all apsects of the adverse affects of risk factors for CVD and to discover new ways to treat 
them and improve prognosis. Numerous risk factors exist for atherosclerosis, including 
anatomical and physiological factors which can be subdivided into various categories such 
as congenital and acquired, modifiable or not, etc. While too numerous to list in their 
entirety, perhaps the most useful of these are those termed classical risk factors. They 
include some of the highest contributors to atherosclerosis, including hypertension, smoking, 
diet and obesity, high blood cholesterol, and diabetes. 
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Hypertension 
 
 Hypertension occurs when the blood pressure in the arteries is elevated and  is 
defined as a systolic pressure greater than 140 mm Hg  and/or a diastolic pressure greater 
than 90 mm Hg. Hypertension is associated with abnormal structural and functional changes 
in the vascular wall and affects more than 77.9 million people in the United States (Go, 
Mozaffarian et al. 2014).  Many mechanisms have been proposed to account for the 
pathogenesis, but generally they include endothelial injury and/or dysfunction, 
hemodynamic factors, cell membrane (ion transport and receptor) abnormalities, 
proliferation and growth of vascular cells, vasoactive substances, platelet dysfunction, and 
lipoprotein deposition and clearance (Dzau 1988). The structural and functional changes in 
the vasculature resulting from hypertension are both caused by and can accelerate the 
development of atherosclerosis. 
 
High Blood Cholesterol  
 
 Cholesterol and triglycerides are transported throughout the bloodstream bound 
within proteins called lipoproteins.  Cholesterol is transported as two major types of  
lipoproteins; low density lipoproteins (LDL) and  high density lipoproteins (HDL). Both 
forms of lipoprotein have significant impacts on atherosclerosis. LDL and its subclasses of 
lipoproteins transfers lipids and cholesterol throughout the circulation, which in turn are 
taken up by cells by receptor mediated endocytosis. This process exacerbates atherosclerosis 
when LDLs are taken up by ECs and other cells within the artery, which can then become 
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oxidized by necrotic cell debris and free radicals (Selwyn, Kinlay et al. 1997). Conversely, 
HDL transports cholesterol and lipids back to the liver for removal from the circulation. 
Blood cholesterol is considered high if the total blood cholesterol concentration is above 240 
mg/dl and/or the ratio of LDL to HDL is greater than 3:1.  High blood cholesterol can be 
caused by several factors, including both genetic and environmental. Genetic or familial 
hypercholesterolemia is caused by a genetic defect on chromosome 19 and is inherited by 
family members in an autosomal dominant manner. This condition causes an accumulation 
of LDL within the bloodstream due to an inability of the body to remove cholesterol. The 
condition begins at birth and can cause cardiovascular dysfunction and atherosclerosis at a 
young age. In addition to genetic defects, environmental factors such as diet, weight, and 
physical activity contribute to hypercholesterolemia and CVD.     
 
Diet and Obesity 
 
 Major risk factors for CVD and atherosclerosis are diet and body mass. Foods such 
as animal products, including meat, cheese, and egg yolks, as well as processed foods and 
those containing saturated and trans fatty acids contain fats which can elevate blood lipid 
and cholesterol levels and lead to weight gain. All other factors being equal, individuals who 
are overweight or obese have a positive correlation with higher LDL levels, lower HDL 
levels, and higher total cholesterol levels, all of which are risk factors and contribute to  
CVD and atherosclerosis. 
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Models of Atherosclerosis  
 
 A wide array of models which mimic aspects of atherosclerosis have been utilized to 
better understand certain characteristics involved in the pathophysiology of the disease and 
include animal,  lower  organism,  genetic,  in  silico, analytical, and kinetic  models (Singh, 
Tiwari et al. 2009).  Among the most commonly used are cellular and animal models which 
throughout the years have provided valuable insight. However, due to the complex and 
multifactoral nature of the disease, no model perfectly replicates human atherosclerosis and 
each model has inherent limitations. Ultimately, any useful disease model should contain 
several aspects, including availability, affordability of establishment and maintenance, ease 
of manipulation, and, most importantly, a close similarity to human disease.    
 
Cellular Models of Atherosclerosis  
 
 Cellular models provide the basis for much of biomedical research currently being 
conducted. Their advantages are their accessibility, affordability, and their ease of 
manipulation. Additionally, cellular models, with the possible exception of human 
embryonic stem cells, carry none of the ethical concerns associated with genetic 
manipulation and drug testing that are seen in animal models. The ability to easily and 
efficiently over-express, knock-down, and silence genes provides a valuable tool for drug 
testing and discovery, as well as  to investigate contributing pathophysiological mechanisms 
and pathways. However, because of the multicellular nature of atherosclerosis, no cell-based 
model faithfully recreates the complex environment or natural progression of the disease. 
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Cell-based models utilize all cellular components, such as T-cells, NKT cells, macrophages 
and endothelial cells. These cells can be both cultured or freshly isolated from human and 
animal models. However, the most utilized model is VSMCs, which comprise the majority 
of the cellular content within the artery and atherosclerotic lesion. With respect to all cellular 
models, it is important to remember that aspects of what occurs within in vitro models of 
atherosclerosis are not always representational or predictive of what occurs within in vivo 
disease states. 
 
Animal Models of Atherosclerosis  
 
 Numerous animal models exist and have been used in the study of the 
pathophysiology of human atherosclerosis. These models range from large animals such as 
rabbits, pigs, and non-human primates to smaller animals such as fish, rats, and mice. While 
no animal model is perfectly identical to human atherosclerosis, each model has its own 
intrinsic advantages and limitations as it pertains to modeling the initial atherogenesis, 
atherosclerotic progression and regression, and manipulation of lipid profiles. Currently, one 
of the most commonly used animal models, due in large part to the ease of genetic 
manipulation and relatively short time period to induce atherosclerotic lesions, is the mouse 
model. The induction of atherosclerosis in murine models of the disease is accomplished in 
two main ways, manipulation of a diet and genetic knockout. Although murine models do 
not naturally develop atherosclerosis on a normal chow, diet induction of atherosclerosis can 
be accomplished with adjustments to calories and fat content. However, not all murine 
strains are equally prone to atherosclerosis while some strains are resistant, the C57BL/6J 
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strain is the most susceptible to atherosclerosis when fed an atherogenic high fat, high 
cholesterol, or cholic acid containing diet (Paigen, Morrow et al. 1987).  
 Alternatively, the induction of atherosclerosis can be achieved through genetic 
manipulation of the model. Several genes have been identified as having a critical role in the 
transport and metabolism of lipids and providing athero-protective benefits. The genetic 
knockout of genes can cause induction of atherosclerosis without the need for  adjustments 
to diet. Two such genes are LDL receptor and apoliporotein E (ApoE), The genetic 
knockout of these genes provides two of the most frequently used models in atherosclerosis 
research. 
 
 ApoE Knockout Murine Model of Atherosclerosis 
 
 Of the murine models of atherosclerosis, one the most frequently used models is the  
ApoE knockout model  (Plump, Smith et al. 1992).  ApoE is a 34kDa lipoprotein that is 
secreted in various cells, such as macrophages, VSMCs and myoblasts, as well as other cells 
in numerous organs such as the liver, lungs, kidneys, and spleen (Beisiegel, Weber et al. 
1988; Koo, Wernette-Hammond et al. 1988). ApoE is a major lipoprotein that exists in 
humans as 3 isoforms, v2, v3, and v4, with ApoE v3 being the most common. ApoE acts as 
a scavenger and transporter of lipids, cholesterol and other associated proteins. Upon 
binding, lipids and cholesterol are transported to the liver for metabolism and further 
processing (Cedazo-Minguez 2007).  In the murine genetic knockout model of ApoE, the 
ApoE gene is excised in a C57BL/6J background, resulting in a strain that spontaneously 
develops and exhibits all stages of atherosclerosis. ApoE knockout mice display a 
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cholesterol level in excess of four times greater than C57BL/6J and this difference can be 
further exacerbated by the addition of a calorie and fat adjusted diet (Zadelaar, Kleemann et 
al. 2007). 
 
Epigenetics 
 
 Epigenetics seeks to describe active alterations in the transcriptional potentiality of a 
cell through the modification of gene expression rather than alteration of the genetic code 
itself (Holliday 1994). Differing from genetics, where changes are based solely on the 
deoxyribonucleic acid (DNA) sequence, the changes in gene expression and cellular 
phenotype associated with epigenetics are due to other causes, primarily modifications of 
DNA, such as methylation and hydroxymethylation of cytosine, covalent modification of 
histones through acetylation, methylation, phosphorylation, ubiquitination, and  sumoylation  
and modification with micro-ribonucleic acids (miRNAs), as well as other members of non-
coding ribonucleic acids (RNAs). Genetics alone cannot account for many diseases' wide 
plethora of transcriptional and phenotypic changes. In this study, we focus on epigenetic 
covalent modifications to DNA in which the prevalence and genomic distribution varies 
widely. This variability may suggest that there are distinct modes of targeting and function 
within atherosclerosis. 
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DNA Methylation and Hydroxymethylation 
 
 The process of methylation allows for a mechanistic way to reversibly create a 
molecular mark on genomic DNA via the addition of a methyl (C-H3) group (Schubeler 
2015). Although bacteria can methylate both adenine and cytosine for processes such as 
tracking mismatched nucleotide repairs or identifying foreign DNA (Arber and Dussoix 
1962; Wion and Casadesus 2006), in eukaryotic cells, methylation only occurs on cytosine 
residues. 
 The discovery that the microinjection of methylated DNA at highly specific sites into 
the nuclei of Xenopus laevis oocytes causes transcriptional inactivation suggested a 
eukaryotic function for DNA methylation (Vardimon, Kressmann et al. 1982). The 
mechanism was later confirmed in cultured mammalian cells with the in vitro methylation of 
the hamster adenine phosphoribosyltransferase gene inhibiting its expression in mouse cells 
(Stein, Razin et al. 1982). These and numerous subsequent studies showed that the 
expression of certain genes may be inhibited by site-specific methylation, functionally 
linking DNA methylation to gene repression.  
 In mammalian somatic cells, methylation primarily occurs when cytosine is followed 
by guanine (CpG), often arranged in clusters called CpG islands that are present in the 5' 
regulatory regions of many genes. Although DNA methylation normally occurs and 
performs its regulatory functions in CpG sites and CpG islands,  non-CpG methylation is 
prevalent in embryonic stem cells (Ramsahoye, Biniszkiewicz et al. 2000).  The sequence 
symmetry of the CpG pairing allows for the heritability of DNA methylation at that 
dinucleotide through cell division. This heritability enables stable epigenetic repression in 
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genomic imprinting, X-chromosome inactivation, and suppression of repetitive elements 
(Jones 2012). In vertebrates, DNA methylation is widespread, with between 60% and 90% 
of CpG sites being methylated in mammals, depending on  the tissue, suggesting it may be a 
default state (Ehrlich, Gama-Sosa et al. 1982).  DNA methylation is traditionally removed 
early on in the formation of the zygote and then later on it is reestablished through 
consecutive cell divisions during early development. 
 
 The mechanism responsible for DNA methylation involves the addition of a methyl 
group to the 5' carbon of a cytosine base by various enzymes termed DNA 
methyltransferases (DNMTs), which can be grouped into two general classes of enzymatic 
activities; maintenance methylation and de novo methylation. Maintenance methylation is 
the process in which the established DNA methylation patterns are copied  to the daughter 
strands during DNA replication. DNMT1 is needed in S phase to methylate newly replicated 
CpGs occurring opposite methylated ones on the mother strand of the DNA and is recruited 
by associated methyl-CpG-binding domain proteins  (Kimura and Shiota 2003; Sharif, Muto 
et al. 2007).  On the other hand, de novo methylation, carried out by DNMT3A and 
DNMT3B in combination with DNMT3L, establishes  patterns of methylation, 
predominantly during gametogenesis and development, that lead to cellular differentiation 
(Okano, Bell et al. 1999; Hata, Okano et al. 2002). 
 Mechanistically there are two ways in which DNA methylation silences gene 
transcription. The methyl (CH3) group can regulate gene expression by modulating and 
physically impeding the interaction between DNA and transcription factors such as RNA 
polymerase, enhancers, and activator proteins  (Choy, Movassagh et al. 2010). Possibility 
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more importantly, DNA methylation can repress transcriptional activity through the 
recruitment and binding of methyl-CpG-binding domain (MBD) proteins such as Methyl-
CpG-Binding Protein 2 (Nan, Meehan et al. 1993).  These MBDs can then bind additional 
proteins, such as histone deacetylases and various other chromatin remodeling proteins 
which, in turn, modify histones, thereby modifying and inactivating chromatin through the 
formation of  heterochromatin (Nan, Ng et al. 1998). 
 
 The removal of methylated cytosine bases occurs in two separate ways; passive and 
active demethylation.   Passive demethylation occurs when there is a failure of maintenance 
methylation, carried out by DNMT1 in S phase, to methylate newly replicated daughter 
strands during DNA replication (Hsieh 1999). Secondly, passive demethylation can occur 
due to cytosine's spontaneous deamination to thymine, which occurs frequently in both 
methylated and non-methylated cytosines throughout the genome (Chen, Ueda et al. 2003). 
In this case the thymine residue is recognized for the thymine/guanosine mismatch, removed 
and repaired through normal base excision repair mechanisms.   
 
 On the other hand, and functionally more important, is active demethylation in which 
removal carried out through oxidation is the best documented. The oxidation of the methyl 
group in 5-methylcytosine (5mC) leads to its conversion to 5-hydroxymethylcytosine 
(5hmC), an alternate DNA pyrimidine nitrogen base. The ten-eleven translocation (TET) 
family of proteins are a group of 2-oxoglutarate (2OG)- and Fe(II)-dependent enzymes that 
catalyzes conversion of 5mC to 5hmC (Tahiliani, Koh et al. 2009). The exact function of 
5hmC is still not fully elucidated, but numerous studies have shown it can activate gene 
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expression and lead to further modifications of the base to convert it back to cytosine. 5hmC 
can be either deaminated by Activation-induced cytidine deaminase (AID) /Apobec 
enzymes to give 5-Hydroxymethyluracil (5hmU) (Guo, Su et al. 2011) or it can be further 
oxidized by TET enzymes to 5-Formylcytosine (5fC) and 5-Carboxylcytosine (5caC) and 
converted back to cytosine  (Globisch, Munzel et al. 2010; He, Li et al. 2011). 
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Figure 3. Epigenetic modifications of cytosine 
Epigenetically important modification to cytosine center around the addition to, and 
modification of, the 5' carbon of cytosine.  Cytosine can be converted by DNA methyl-
transferases (DNMTs) to form 5-methycytosine (5mC). 5mC can either be converted to 
thymine and converted back to cytosine through base excision repair (BER) or converted to 
5-hydroxymethylcytosine (5hmC) by ten-eleven translocation (TET) enzymes. 5hmC can be 
either deaminated by AID /Apobec enzymes to give 5-Hydroxymethyluracil (5hmU) (Guo, 
Su et al. 2011)or it can be further oxidized by TET enzymes to 5-Formylcytosine (5fC) and 
5-Carboxylcytosine (5caC) and converted back to cytosine  (Guo, Su et al. 2011) (Globisch, 
Munzel et al. 2010; He, Li et al. 2011). Finally, all cytosine modification can passively be 
demethylated during DNA replication.  
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DNA Methylation in Atherosclerosis  
 
 Epigenetic studies into atherosclerosis focusing on DNA methylation date back over 
15 years, first focusing on single genes and progressing to genome wide analyses. These 
studies have provided firm evidence that not only does DNA methylation exist within 
certain genes but, as in the case of estrogen receptor gene alpha (ER alpha), methylation can 
greatly affect expression during atherogenesis (Post, Goldschmidt-Clermont et al. 1999).   
 
Several types of cells, including monocytes and lymphocytes have been studied for 
alterations in the patterns of DNA methylation. These cell types have been studied not only 
for their contribution to atherosclerosis, but also the ease of attainability. Genome-wide 
studies have revealed a global hypomethylation and have proposed elevated homocysteine 
levels, a known risk factor for CVD, as a possible mechanism.  High levels of circulating 
homocysteine has the ability to inhibit DNMT  (Castro, Rivera et al. 2003).  Aside from 
DNA methylation, little information is known about the contribution of hydroxymethylation 
in atherosclerosis. 
 
Mechanistic Target of Rapamycin (mTOR) 
 
 Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase 
originally indentified as a mammalian protein targeted by the G1-arresting rapamycin-
receptor complex (Brown, Albers et al. 1994). mTOR acts as the catalytic subunit of two 
structurally distinct complexes: mechanistic target of rapamycin complex 1  (mTORC1) and 
mechanistic target of rapamycin complex 2  (mTORC2) (Kunz, Henriquez et al. 1993; 
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Helliwell, Wagner et al. 1994). Both complexes localize to different subcellular 
compartments, thus affecting their activation and function and have regulatory functions 
including cell growth, cell proliferation, cell motility, cell survival, protein synthesis, 
autophagy, and transcription (Hay and Sonenberg 2004).  
 mTORC1 is composed of mTOR, regulatory-associated protein of mTOR (Raptor), 
mammalian lethal with SEC13 protein 8 (MLST8) and the non-core components PRAS40 
and DEPTOR (Kim, Sarbassov et al. 2002; Kim, Sarbassov et al. 2003). This complex 
functions as a nutrient/energy/redox sensor and controls protein synthesis The activity of 
mTORC1 is stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids, 
and oxidative stress (Fang, Vilella-Bach et al. 2001). 
 mTOR Complex 2 (mTORC2) is composed of mTOR, rapamycin-insensitive 
companion of mTOR (RICTOR), MLST8, and mammalian stress-activated protein kinase 
interacting protein 1 (mSIN1)(Frias, Thoreen et al. 2006). mTORC2 has been shown to 
function as an important regulator of the cytoskeleton through its stimulation of F-actin 
stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα) (Sarbassov, Ali et 
al. 2004). 
 Reports over the last few years clearly demonstrates that mTOR exerts its regulatory 
functions through a very large number of downstream targets, some of which are 
phosphorylated directly by mTOR, but many are phosphorylated indirectly. 
 
 
 
 
23 
Insulin-like growth factor 1 (IGF-1) 
 
 Insulin-like growth factor 1 (IGF-1) is a hormone that shares a similarity  in 
molecular composition to insulin. It plays a critical role in cellular signaling transduction 
and  regulates cell growth, differentiation, apoptosis, transformation and other important 
physiological processes.  Its primary function  is acomplished by binding to its specific 
receptor insulin-like growth factor 1 receptor (IGF-1R), a tyrosine kinase growth factor 
receptor. IGF-1R mainly engages in the Ras/mitogen-activated protein kinase (MAPK) 
pathway and also forms cross-talk with the epidermal growth factor receptor (EGFR) 
pathway. Notably. it engages in the the phosphoinositide 3-kinase/protein kinase B 
(PI3K/AKT) pathway and its downstream partner, mTOR. In cardiovascular diseases, 
evidence suggests it may regulate contractility, metabolism, hypertrophy, apoptosis, 
autophagy, stem cell regeneration and senescence (Ren and Anversa 2015). 
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Chapter 2: Hypothesis and Aims  
 
 
Rationale  
 
 Epigenetics play an important role in vascular biology and disease. Studies of 
epigenetic profiles in atherosclerosis have been focused on DNA methylation and date back 
over 15 years, analyzing from single gene modifications to genome wide DNA methylation 
profiles. These studies have provided firm evidence that not only does DNA methylation 
exist within certain genes but, as in the case of estrogen receptor gene alpha (ER alpha), 
methylation can greatly affect expression during atherogenesis (Post, Goldschmidt-Clermont 
et al. 1999).  The majority of these studies have utilized bisulfite conversion of methylated 
DNA, which although valuable cannot distinguish between DNA methylation and 
hydroxymethylation marks.  Bisulfite conversion, also known as bisulfite treatment, is a 
molecular process which deaminates unmethylated cytosine bases to produce uracil in DNA.  
Bisulfite conversion is largely considered to be the "gold standard" to test numerous 
downstream applications assessing the methylation status of DNA. Methylated or 
hydroxymethylated cytosines bases are protected from the conversion to uracil, allowing the 
use of other applications to determine the locations and frequencies of unconverted 
cytosines at a single-nucleotide resolution (Frommer, McDonald et al. 1992). Although this 
has long been the "gold standard" the inability to differentiate methylation and 
hydroxymethylation is an important consideration because the functional consequences of 
these two modifications are very different. Therefore, to determine what contribution is 
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made by DNA hydroxymethylation tools that can accurately differentiate both modifications 
should be utilized. 
 The long term goal of this research is to elucidate the contribution of the epigenetic 
mechanisms of DNA methylation and hydroxymethylation to the pathophysiological process 
of vascular cell differentiation during atherogenesis.  
 
Hypothesis 
 
 Abnormal epigenetic regulation of vascular cell gene expression contributes to the 
pathogenesis of atherosclerosis in the arterial wall exposed to environmental risk factors, 
such as hypercholestolemia and hypertension, by up-regulating harmful genes and down-
regulating protective genes. These aberrant expression patterns will lead to a differentiation 
from a contractile to synthetic phenotype and the exacerbation of atherosclerosis. Therefore 
the specific aims of these studies are:  
 
Specific Aims 
 
Aim 1: 
To determine the contribution of DNA methylation and hydroxymethylation to the 
epigenome of vascular smooth muscle cells during the process of atherogenesis. 
 1.1)  To create an in vivo mouse model representative of the stages of the complex 
  multifactorial nature of atherosclerosis. 
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 1.2)  To determine the genome-wide epigenomic contribution of DNA   
  methylation and hydroxymethylation and their relative ratios to diseased and 
  healthy states in the murine atherosclerosis model. 
 1.3) To determine the locus specific DNA methylation and hydroxymethylation 
  alterations during the process of atherogenesis and identify specific genes  
  affected.  
Aim 2: 
To determine the mechanisms that impact the relative amounts and contributions of DNA 
methylation and hydroxymethylation in the epigenome of vascular smooth muscle cells 
during the process of atherogenesis. 
 2.1)  To determine which members of TET family of DNA hydroxylases are  
  involved in the conversion of DNA methylation to hydroxymethylation and 
  subsequent gene activation during the process of atherogenesis. 
 2.2) To determine the mechanism by which the involved TET enzymes are  
  regulated in atherogenesis and to test whether the pathway promotes the  
  contractile VSMC to dedifferentiate to a synthetic phenotype by altering  
  DNA  methylation/hydroxymethylation.  
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Chapter 3: Materials and Methods 
 
 
Murine Models of Atherosclerosis 
 
 Atherosclerosis-prone ApoE knockout and C57BL/6J Wild Type mice (male, 3 
months old) were obtained commercially from Jackson Laboratory and were housed in a 
climate-controlled environment (Plump, Smith et al. 1992). Mice were fed for a period of 15 
weeks with either normal chow (TD.05230  Mouse/Rat Sterilizable Diet, containing 6.2% 
kcal from fat) or a western diet (TD.88137 Mouse/Rat Adjusted Calories Diet, containing  
47% kcal from fat) (Teklad Lab Animal Diets, Harland Laboratories). All experimental 
procedures and protocols used in this investigation were reviewed and approved by the 
Institutional Animal Care and Use Committee of The University of Texas Health Science 
Center at Houston.  
 
Determination of Body Weight/Body Mass Index 
 
 Mice were anesthetized with a 2% isoflurane/oxygen mixture using a VetFlo Rodent 
Anesthesia Vaporizer (Kent Scientific ) and weighed using a digital centigram balance 
(Intell-Lab). Body mass index was calculated using average body length measured from the 
tip of the snout to the anus and using the following formula: 
BMI = Body Weight (kg)/Body Length (meter)
2
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Analysis of Blood Pressure 
 
 Mice were placed in plastic restrainers and, when the animals relaxed, a volume 
pressure recorder cuff was gently attached to the tail. Mice were allowed to habituate to this 
procedure for 7 days prior to the experiments being performed. Systolic and diastolic blood 
pressure values were recorded on a CODA-HT8 (Kent Scientific) and were averaged from 
ten consecutive readings obtained from each mouse. Mean arterial pressure was calculated 
using the formula (MAP = [(2x diastolic)+systolic]/3). 
 
Collection of Blood Samples  
 
 Blood collection was done under general anesthesia with a 2% isoflurane/oxygen 
mixture using a VetFlo Rodent Anesthesia Vaporizer (Kent Scientific). Using heparinized 
micro-hematocrit capillary tubes (Fisherbrand), 200 ul of whole peripheral blood was 
collected from the medial canthus via retro-orbital puncture of the sinus membrane. Blood 
serum was separated with an Eppendorf  5424 centrifuge at  2,000 x g for 10 minutes.  Lipid 
profile containing HDL, VLDL, LDL, Triglycerides, and Cholesterol was analyzed  (Equine 
Laboratories). 
 
Ultrasound Assessment   
 
 Echocardiography was performed under anesthesia with a 2% isoflurane/oxygen 
mixture using a VetFlo Rodent Anesthesia Vaporizer (Kent Scientific). Mice were placed on 
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a rodent warming pad and extremities were fixed by gently placing the mouse in a supine 
position. Precordial areas were cleaned by pre-warmed hair removal gel (Nair) left on skin 
briefly for 1-2 minutes. Echocardiography was performed using Vevo 2100 ultrasound 
machine and  Visualsonics software (FUJIFILM VisualSonics, Inc). The following 
echocardiographic and transthoracic aortic parameters were recorded with a RMV 704 
(Real-Time Micro Visualization) scanhead with traducer frequency at 50 MHz in B and M-
Modes: Heart rate, left ventricular (LV) diameters (systolic and diastolic, s/d), LV ejection 
fraction, fractional shortening, LV wall thickness, LV wall motion abnormalities (defined as 
basal and apical-mid segments), and aortic intimal thickness.   
 
Collection of Aortic Tissue 
 
 Mice were anesthetized with a 2% isoflurane/oxygen mixture using a VetFlo Rodent 
Anesthesia Vaporizer (Kent Scientific) and were euthanized by cervical dislocation. Whole 
aortic tissues were excised starting at the aortic valve to the abdominal aorta approximately 
8 mm prior to the iliac bifurcation.  Aortic tissue was  processed for extraction of DNA, 
RNA, proteins, and preparation for sectioning. 
 
Isolation of Genomic DNA 
 
 Total DNA was obtained from cell cultures and aortic arch tissue approximately 5 
mm from the outlet of the aortic valve. Aortic tissue was manually separated removing 
adventitial connective tissue and endothelium.  Medial tissue was then incubated for 10 min 
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at 37
o
 C  with collagenase type II (Worthington Laboratories) and resulting cells were 
subjected to further processing.  Extraction was done using DNeasy column collection kit 
(QIAGEN) per manufacturer's instructions. Extracted DNA was quantified with a DU 730 
UV/Vis Spectrophotometer (Beckman Coulter) and was stored at -80
o
 C. 
 
Isolation of RNA 
  
 Total RNA was obtained from cell cultures and aortic arch tissue approximately 
5mm from the aortic valve. Aortic tissue was manually separated removing adventitial 
connective tissue and endothelium. Medial tissue was then incubated for 10 min at 37
o
 C  
with collagenase type II (Worthington Laboratories) and resulting cells were subjected to 
further processing. Extraction was done using TRIzol reagent (Invitrogen) and purified with 
RNeasy Plus RNA preparation kit (QIAGEN) ) per manufacturer's instructions. Extracted 
RNA was quantified using a DU 730 UV/Vis Spectrophotometer (Beckman Coulter) and 
was stored at -80
o
 C. 
 
Protein Extraction 
 
 Protein was extracted from cell cultures and aortic arch tissue approximately 5 mm 
from the aortic valve. Aortic tissue was manually separated removing adventitial connective 
tissue and endothelium. Medial tissue was then incubated for 10 min at 37
o
 C  with 
collagenase type II (Worthington Laboratories) and resulting cells were lysed in 
solubilisation buffer (50 mM HEPES, pH 7.5; 150mM NaCl; 1mM EGTA; 20mM_-
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glycerophosphate; 1% Nonidet P-40; 10 mM NaF; 2 mM Na3VO4; and protease inhibitors). 
Protein fractions were separated with a 5424 centrifuge (Eppendorf) at  2,000 x g for 10 
minutes and stored at -80
o 
C. 
 
Isolation and Culture of VSMC 
 
 VSMC were isolated and cultured from the aortic tissues of Wild Type and ApoE-/- 
mice (male, 6 months old). After removing adventitial connective tissue and endothelium, 
medial muscle cells were dispersed by incubation for 10 minutes with 10 uM collagenase 
type II (Worthington Laboratories). Cells were cultured in DMEM medium (Sigma) 
supplemented with 10% lipoprotein deficient serum (LPDS). Cells were identified as VSMC 
by their “hill and valley” growth pattern and cell populations (α-SMA+ SM-MHC+) were 
isolated and analyzed by fluorescence activated cell sorting (FACS)(BD ARIA).  
 
Aortic Tissue Sectioning and Histopathological Analysis  
 
 Whole aortic arch tissue was placed in precast polyethylene molds filled with 
Optimal Cutting Temperature (OCT) frozen tissue matrix (Tissue-Tek). Molds were placed 
on dry ice and the tissue matrix was allowed to solidify completely.  Sections were cut to 5-
8 µm with a CM1800 cryostat microtome (Leica) set to -20°C.  Sections were placed on  
Fisher Superfrost ( Fisher Scientific) slides and allowed to dry at room temperature (RT) and 
stored for at -80°C in a sealed slide box. General aortic morphology was determined by 
hemotoxilin and eosin (H&E) staining and analyzed using an Olympus BX60 microscope. 
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Oil Red O Staining of Aortic Tissue Sections 
 
 For assessing neural lipid accumulation in aortic tissues, Oil Red O staining was 
conducted in frozen sections (8 μm) and whole en face longitudinal aortic arch sections. 
Sections were placed on slides the slides were washed with running tap water and mounted 
in aqueous mountant (Thermo Scientific). Images were recorded and analyzed with an 
Olympus BX60 fluorescence microscope connected with Cambridge Research and 
Instrumentation's Nuance multispectral imaging system EX. Image cubes were autoexposed 
and colorimetric signals were spectrally unmixed and then manually computed, comparing 
known signals to autofluorescence to create the spectral library. Acquired cubes were 
unmixed and batch processed using the spectral library to create final images. Quantification 
of Oil Red O staining within the sections was done with serial images and inForm software 
(CRi).  
 
Determination of Global DNA Methylation in VSMCs and Aortic Tissues  
 
 DNA extracted from VSMC and aortic tissue was analyzed using 800 ng genomic 
DNA and Quest 5-mC DNA enzyme-linked immunosorbent assay   (ELISA) Kit (Zymo 
Research) per manufactures' instructions 
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Determination of Global DNA Hydroxymethylation in VSMCs and Aortic Tissues 
 
 DNA extracted from VSMC and aortic tissue was analyzed for global DNA 
hydroxymethylation by T4 Phage β-glucosyltransferase treatment of DNA and analyzed 
using 800 ng genomic DNA and Quest 5-mC DNA ELISA Kit (Zymo Research) per 
manufacturer's instructions.  
 
Locus Specific DNA Hydroxymethylation  Detection in VSMC and Aortic Tissues 
 
 Sequence-specific detection  of DNA hydroxymethylation  was performed with the 
Quest 5-hmC Detection Kit (Zymo Research) per manufacturer's instructions. Genomic 
DNA (1 μg) was treated with T4 Phage β-glucosyltransferase. Glucosylated genomic DNA 
was then digested with MspI, which recognizes and cleaves cytosine, methylcytosine, 
hydroxymethylcytosine,  but not glucosyl-5-hmC hydroxymethylcytosine at CCGG loci. 
Locus-specific detection of 5-hydroxymethylcytosine was determined by quantitative 
polymerase chain reaction (qPCR) using primers designed to flank at least one MspI site. 
 
Locus Specific DNA Methylation  Detection in VSMC and Aortic Tissues 
 
 Sequence-specific detection of 5- methylcytosine was performed with the Quest 5-
mC Detection Kit (Zymo Research) per manufacturer's instructions. Genomic DNA (1 μg) 
was treated then digested with MspI, which recognizes and cleaves cytosine, 
hydroxymethylcytosine but not  5- methylcytosine at CCGG loci. Locus-specific detection 
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of 5-methylcytosine was determined by qMethyl qPCR using primers designed to flank at 
least one MspI site. 
 
Table 1. Quantitative Polymerase Chain Reaction (qPCR) Primers 
Primer Sequence 
IGF-1R Forward  5'-GTCTGGGTTCCCTTTCCAGG-3' 
IGF-1R Reverse  5'-CCCTGAAGACTGCTACGCAA-3' 
IGF-1R Forward 5'-TTGCCCTAAAACTGAAGCTGA-3' 
IGF-1R Forward Locus 1 5'-GAGAATAGAGCCTCGCGGAC-3' 
IGF-1R Reverse Locus 1 5'-GACCCCTGAAGACTGCTACG-3' 
IGF-1R Forward Locus 2 5'-GCGTAGCAGTCTTCAGGGGT 
IGF-1R Reverse Locus 2 5'-ACTCCGTGAAAAAGCTTCATTGTT-3' 
IGF-1R Forward Locus 3 5'-AAAGCCTCGTCTTGGGGAAA-3' 
IGF-1R Reverse Locus 3 5'-GCTCGGGTCCCAGTCTTAGG-3' 
IGF-1R Forward Locus 4 5'-CTTCGGTGCAGGGAATGCTC-3' 
IGF-1R Reverse Locus 4 5'-ACCGGAAACTTGCCTTGTTTT-3' 
IGF-1R Reverse 5'-GTTCTCGCAAAGACGAAGTTG-3' 
GAPDH Forward 5'-AGGTCGGTGTGAACGGATTTG-3' 
GAPDH Reverse 5'-TGTAGACCATGTAGTTGAGGTCA-3' 
mTOR Forward 5'-ACTGAGGAGGGAGAACAGCA-3' 
mTOR Reverse 5'-CCAGTTGGTAACAATGCCATGT-3' 
TET1 Forward  5'-GCAGCGTACAGGCCACCACT-3' 
TET1 Reverse 5'-AGCCGGTCGGCCATTGGAAG-3' 
TET2 Forward 5'-TTCGCAGAAGCAGCAGTGAAGAG-3' 
TET2 Reverse 5'-AGCCAGAGACAGGGGATTCCTT-3' 
TET3 Forward  5'-GACGAGAACATCGGCGGCGT-3' 
TET3 Reverse 5'-GTGGCAGCGGTTGGGCTTCT-3' 
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Western Blot Analysis 
 
 Total proteins extracted from aortic tissue or cultured cells by RIPA buffer (Sigma) 
were analyzed by western blot with the following antibodies/dilutions: rabbit monoclonal               
anti-IGF-1R / 1:1000 (Cell Signaling) mouse monoclonal Anti-Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) / 1:1000 (Sigma, USA), mouse monoclonal anti-TET1 / 1:1000 
(Abcam), mouse monoclonal anti-TET2 / 1:1000 (Abcam), and mouse monoclonal anti-
TET3 / 1:1000 (Abcam). Equal amounts of proteins were loaded on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gels, separated by electrophoresis and 
electroblotted to a polyvinylidene difluoride (PVDF) membrane. After incubation with 
corresponding secondary antibodies conjugated with horse radish peroxidase (HRP): Goat 
anti-rabbit IgG, HRP-linked antibody / 1:5000 (Sigma, USA) and Donkey anti-goat 
immunoglobulin G (IgG), HRP-linked antibody / 1:5000 (Sigma). Immunoreactive bands 
enhanced with chemiluminescence (ECL) per manufacturer's instructions (Amersham) and 
were visualized with a Gel Doc XR+ Imaging System (Bio-Rad). 
 
Immunofluorescence Microscopy 
 
 Frozen sections fixed in cold acetone were blocked with 5% bovine serum albumin 
(BSA), 22.52 mg/ml glycine in phosphate buffered saline (PBS) + 0.1% Tween 20 (PBS-T) 
for 30 minutes, sections were incubated with the following primary antibodies/dilutions: 
rabbit monoclonal anti-IGF-1R / 1:200 (Cell Signaling), mouse monoclonal anti-TET1 / 
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1:200 (Abcam), mouse monoclonal anti-TET2 / 1:200 (Abcam), and mouse monoclonal 
anti-TET3 / 1:200 (Abcam) rabbit monoclonal anti-mTORC1 / 1:200 (Abcam)  and mouse 
monoclonal anti-SM-actin / 1:200 (Sigma). The sections incubated with non-specific IgG set 
up as negative controls. Sections were washed and incubated with appropriate Alexa488 and 
Alexa594 1:500 conjugated secondary antibodies (Invitrogen). Sections were washed and 
mounted with 4',6-diamidino-2-phenylindole (DAPI)-containing Vectashield medium 
(Vector Laboratories). Immunofluorescent images were recorded and analyzed under 
Olympus FluoView FV1000 confocal microscope and Olympus BX60 fluorescence 
microscope connected with Cambridge Research and Instrumentation's Nuance multispectral 
imaging system EX. Image cubes were autoexposed and fluorescent signals were spectrally 
unmixed and then manually computed, comparing known signals to autofluorescence to 
create the spectral library. Acquired cubes were unmixed and batch processed using the 
spectral library to create final images.  
 
mTOR Inhibitor Treatment  
 
 VSMCs were treated with rapamycin (25 nM), torin (15 nM) or vehicle 
dimethylsulfoxide (DMSO), 0.01%  in DMEM 10% fetal bovine serum (FBS) for 6,12,18 
or 24 h. After incubation cells were washed and total RNA was extracted for reverse 
transcription quantitative polymerase chain reaction (RT-qPCR). 
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Statistical Analysis 
 
 Data was analyzed using GraphPad Prism (GraphPad Software Inc.). Comparisons 
between matched pairs were performed using the Student’s t-test. Multiple comparisons 
were performed using one-way analysis of variance (ANOVA) followed by the appropriate 
post-hoc test. A p-value less than 0.05 was considered significant. 
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Chapter 4: Results  
 
 
The Development of Atherosclerosis in Diet Induced and Genetically Modified Mice 
  
 One of the leading risk factors for atherosclerotic vascular diseases is high lipid 
concentrations  in the blood stream. In mice lacking the ApoE gene there is an increased 
lipid content in peripheral blood. On the other hand, these lipid levels can be modified 
through alterations in diet, creating susceptibility for atherosclerotic vascular diseases. To 
assess the development of atherosclerosis, we evaluated common areas of cardiovascular 
health such as weight, blood pressure, cardiac function, and aortic intimal thickness.  
 
Assessment of Obesity in  the Development of Atherosclerosis. 
 
 Various measures of obesity, including weight and BMI, have all showed a positive 
correlation between obesity and cardiovascular diseases, including atherosclerosis 
(Montenegro and Solberg 1968). To study the relationship between epigenetic alterations 
and atherosclerosis, a murine model of atherosclerotic plaque formation was induced via 
alteration of diet and/or knockout of the ApoE gene. Wild type and ApoE deficient mice fed 
a normal diet or chow consisting of 47% fat/kCal were studied, using animal weight as an 
initial indication of atherogenesis. Representative images show a visual increase in body 
weight and overall mass of both groups, wild type and ApoE, when subjected to a high fat 
diet (Figure 4). Average body weight was significantly increased between wild type mice 
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and wild type fed a high fat diet showing an average weight increase of 5.9 ± 1.3 grams 
(P≤0.001).  ApoE fed a high fat diet showed a more significant average increase in weight of 
8.1 ± 1.0 grams (P<0.0001) vs. ApoE mice fed normal chow diet (Figure 5).  
 
 
 
 
 
                WT                                APOE                             WT HF                       APOE HF 
Figure 4.   Diet induced changes in wild type and ApoE knockout mice.  
Representative images of wild type and ApoE mice fed normal or high fat (HF) diet 
demonstrating an increase in weight and BMI.    
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Figure 5. Average body weight in wild type and ApoE knockout  mice fed normal or 
high fat diets. 
Average body weight of wild type and ApoE deficient mice fed normal and high fat diet. 
Addition of a high fat diet causes a marked increase in the average body weight in both 
wild-type and ApoE deficient mice   (n=8/group).  
 
 
 Consistent with weight gain through high fat diet induced obesity, wild type and 
ApoE deficient mice subjected to a high fat diet showed an increase in BMI. Average body 
mass was significantly increased between wild type mice and wild type fed a high fat diet, 
with an average BMI increase of 0.7 ± 0.2 kg/m
2
 (P≤0.0001).  ApoE mice and ApoE fed a 
high fat diet showed a greater average increase in BMI of 1.0 ± 0.1 kg/m
2
 (P≤0.0001).  
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Figure 6. Body mass index changes in wild type and ApoE knockout mice fed normal 
and high fat diets. 
Body mass index of wild type and ApoE deficient mice fed normal and high fat diets 
(n=8/group). BMI calculated using weight divided by average body length squared (kg/m
2
). 
Average BMI of wild type C57Bl6J strain shown in red line from published data (Svenson 
KL 2015). 
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Assessment of Hypertension in  the Development of Atherosclerosis. 
 
 Obesity resulting from high fat feeding of mice produces hyperlipidemia. Increases 
in lipid profiles, whether diet or genetic knockout induced,  in turn, causes changes in the 
cellular and molecular mechanisms which have been shown to cause hypertension. 
Hypertension is not only a well-established cardiovascular risk factor, but also increases the 
risk of atherosclerosis (Alexander 1995). Thus, we next sought to assess the effect of diet 
and genetic knockout-induced hyperlipidemia on hypertension. Blood pressure was 
measured using the tail-cuff method.  ApoE deficient mice showed an increase in the 
average systolic and diastolic pressure as compared to wild type  (P<0.005).  When 
subjected to high fat diet, both wild type and ApoE deficient mice showed an increase in 
both systolic and diastolic blood pressure over groups fed normal chow. Of the four groups, 
ApoE deficient fed a high fat diet showed the highest proclivity for hypertension, with five 
of eight mice defined as hypertensive or pre-hypertensive as characterized by a systolic 
pressure over 130 mmHg and a diastolic pressure over 90 mmHg.  
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Figure 7.  Systolic blood pressure of wild type and ApoE knockout mice fed normal or 
high fat diets. 
Average systolic blood pressure by tail cuff method of wild type and ApoE deficient mice 
fed normal or high fat diets (n=8/group). 
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Figure 8.  Diastolic blood pressure of wild type and ApoE knockout mice fed normal or 
high fat diets. 
Average diastolic blood pressure by tail cuff method  of wild type and ApoE deficient mice 
fed normal and high fat diets (n=8/group). 
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Figure 9.  Mean arterial blood pressure of wild type and ApoE knockout mice fed 
normal or high fat diets. 
Average mean arterial blood pressure derived from systolic and diastolic pressure of wild 
type mice and ApoE deficient mice fed normal or high fat diets. (MAP = [(2x 
diastolic)+systolic]/3)  (n=8/group). 
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Assessment of Cardiac Function in  the Development of Atherosclerosis. 
 
 Atherosclerosis is commonly diagnosed in a clinical setting utilizing medical and 
family histories, a physical exam, and various test results. Apart from diagnosis, some 
methods allow atherogenesis to be visualized and quantified directly though imaging 
modalities. One of the most commonly used modalities to assess cardiovascular function is 
echocardiography. Thus, we next sought to indirectly assess  overall vascular health by its 
relation to cardiac function in diet-adjusted and/or genetic knockout-induced atherosclerosis.  
 
 
Figure 10. Echocardiography of wild type and ApoE knockout mice. 
Representative echocardiographic images of left ventricles in M-mode of wild type (A) and 
ApoE knockout (B) showing left ventricular wall and interventricular septal thickness 
(denoted with green *).  (LVID;s = left ventricular internal diameter systolic, LVID;d = left 
ventricular internal diameter diastolic, IVS;sD = interventricular septal systolic diameter, 
IVS;dD =  interventricular septal diastolic diameter, LVPW;s = left ventricular posterior 
wall systolic, LVPW;d =  left ventricular posterior wall diastolic) 
* 
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 Overall evaluation of  echocardiograms  of ApoE knockout mice show an increase in  
left ventricular wall and interventricular septal thickness as compared to wild type mice 
(Figure 10). Furthermore, transthoracic echocardiographic measurements showed a 
significant  decrease in fractional shortening,  left ventricular internal diameter during 
systole (LVID;s), left ventricular internal diameter during diastole (LVID;d) and an  increase 
in the interventricular septal diameter (IVS) that was exacerbated by the addition of high fat 
diet feeding and the genetic knockout of ApoE (P <0.05) (Table 2).   
 
Table 2. Echocardiographic measurement of heart function and wall motion in wild 
type and ApoE mice fed normal or high fat diets. 
Animal Group Wild Type Wild Type High Fat ApoE
-/-
 ApoE
-/- 
High Fat 
Heart Rate (beats/min) 399±19 416±21 394±15 395±17 
Fractional Shortening (%) 37.7±1.2 32.5±1.5* 32.1±1.9* 29.5±2.1*† 
LVID;s (mm) 2.89±0.09 2.81±0.11 2.48±0.07*† 2.46±0.06*† 
LVID;d (mm) 4.64±0.08 4.16±0.13* 3.65±0.09*† 3.49±0.11*†‡ 
IVS (mm) 1.09±0.05 1.21±0.1* 1.24±0.09*† 1.31±0.07*†‡ 
Transthoracic echocardiographic measurements in M-Mode of mice. Values represented as  
Mean ± SEM (n=8/group). 
 
*Significant difference vs Wild Type mice. 
†Significant difference vs Wild Type High Fat mice ApoE-/- mice. 
‡Significant difference vs ApoE-/- mice. 
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Transthoracic Aortic Ultrasound Assessment in the Development of Atherosclerosis. 
 
 There is close association between cardiac hypertrophy and dysfunction and vascular 
health due to the causative nature of vascular thickening, occlusion, and stenosis  associated 
with atherosclerosis. Thus, to assess vascular health and function during the progression of 
atherosclerosis, we next sought to evaluate aortic arch  intimal thickness via transthoracic 
aortic ultrasound (Figure 11).  
 
 
  
Figure 11. Ultrasound examination of arterial gross anatomy  in wild type mice. 
Representative transthoracic echocardiography showing the location of  aortic arch (denoted 
with green box).  Measurements taken  in B-mode during systole. 
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Figure 12. Ultrasound examination of aortic intimal thickness. 
Representative transthoracic echocardiographic measurements of aortic arch intimal 
thickness  in B-mode of wild type and ApoE knockout fed normal chow, (A) and (B) 
respectively, and wild type and ApoE knockout fed a high fat diet, (C) and (D) respectively.  
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 Significantly increased average intimal thickness was observed within the aortic arch  
of wild type mice subjected to a high fat diet as compared to wild type control (P=0.03). 
Similarly, an increase in  intimal thickness was observed between wild type and ApoE 
knockout mice fed a normal diet (P=0.004), with the most dramatic increase seen in ApoE 
knockout mice fed a high fat diet, as compared to wild type control mice (P=0.001)        
(Figure 13).  
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Figure 13. Average aortic intimal thickness by ultrasound examination. 
Average transthoracic aortic intimal thickness measurements by ultrasound examination  in 
B-mode of wild type and ApoE knockout mice fed normal or high fat diets  (n= 3/group). 
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Ex Vivo Assessment of Lipid Inclusion in Atherosclerosis 
  
 Extracellular lipid accumulation and intracellular lipid inclusion via endocytosis is a 
central mechanistic process in the development of atherosclerotic progression. To visualize 
the inclusion of neutral lipids within the atherosclerotic plaque, whole longitudinal aortic 
arch sections were taken from wild type and ApoE mice fed either a normal or high fat diet 
and stained with Oil Red O.  Marked increases in number and severity of plaques were seen 
in ApoE mice as compared with wild type. Additionally, Oil Red O staining was increased 
in both groups with the addition of a high fat diet (Figure 14).   
 Next, transverse aortic arch sections were stained with Oil Red O. As expected, 
atherosclerosis prone ApoE deficient mice fed normal chow developed fibrous plaques in 
the aortic wall.  Conversely, no atherosclerotic lesions existed in sex- and age-matched wild 
type mice, and only intermittent small areas showed any lipid inclusion (Figure 15). 
 Finally, serial transverse aortic arch sections were stained with Oil Red O and 
showed significant increases in the quantification of staining in ApoE mice as compared 
with wild type, which was further increased with the addition of a high fat diet (P<0.05) 
(Table 3).  
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Figure 14 En face Oil Red O staining of whole aortic arch segments of WT and ApoE 
mice fed normal or high fat diets. 
(A) Representative area of whole aortic arch segment taken for analysis of lipid inclusion 
and plaque formation. Oil Red O staining of whole aortic arch segments in (B)wild type 
normal diet, (C) wild type fed a high fat diet (D) ApoE normal diet, and (E) ApoE fed a high 
fat diet.  
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Figure 15. Oil Red O staining of aortic wall sections from wild type and ApoE 
knockout mice.  
Representative aortic arch cross section of wild type (A) and ApoE (B) stained for             
Oil Red O. 
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Table 3. Quantification of atherosclerotic plaques stained with Oil Red O. 
 
 Wild Type ApoE
-/-
 
Normal Diet  1.1±0.3 25.3±3.2 * 
High Fat Diet 16.7±5.3 *† 31.9±7.8 *†‡ 
 
Quantification of Oil Red O staining within the aortic arch with serial cross section images 
obtained using Nuance TRIO(CRi)  multispectral analysis and inForm software. Data is 
expressed as Means ± SEM, statistical analysis via One-way ANOVA (n=8/group) 
*Significant difference vs Wild Type mice. 
†Significant difference vs Wild Type High Fat mice ApoE-/- mice. 
‡Significant difference vs ApoE-/- mice. 
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Global DNA methylation and hydroxymethylation in the aortas of wild type and ApoE 
knockout mice fed normal or high fat diets.  
 
 Aberrant DNA methylation is related not only to aging, but  also the onset and 
progression of numerous diseases, and, because of its affect on numerous gene promoters, 
aberrant methylation patterns may be an important contributor to the progression of 
atherosclerosis (Dong, Yoon et al. 2002). To test whether DNA methylation differed during 
the progression of atherosclerosis global 5-methylcytosine levels were analyzed. A positive 
correlation was observed between global demethylation and knockout of ApoE, as well as, 
the addition of a high fat diet (P<0.05) (Figure 16).  The greatest progression of 
atherosclerosis, as evidenced by physiological and ex vivo examination,  was seen in the 
ApoE genetic knockout group fed a high fat diet which showed the greatest average 
demethylation as compared to the wild type group fed normal chow (P<0.001).   
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Figure 16. Assessment of Global DNA methylation levels in wild type and ApoE 
knockout mice fed normal or high fat diets. 
Quantification of global 5-methylcytosine concentration within aortic arch of wild type and 
ApoE deficient mice fed normal or high fat diet. Analysis via 5-mC ELISA (n=8/group). 
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 Because aberrant DNA methylation patterns are common to diseased states, and 
because aberrant 5-methylcytosine levels were observed during the progression of 
atherosclerosis, we next analyzed global 5-hydroxymethylcytosine levels. Fluorescence 
microscopy of whole aortic sections provides unclear expression levels (Figure 17), 
however, similar to 5-methylcytosine levels, there was a positive correlation between global 
loss of hydroxymethylation and the level of atherosclerosis as assessed by DNA ELISA. The 
ApoE genetic knockout group fed a high fat diet showed the largest global loss of 5-
hydroxymethycytosine as compared to the control wild type group fed normal chow 
(P<0.01) (Figure 18). 
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Figure 17.  In situ fluorescence microscopy of DNA hydroxymethylation 
Fluorescence microscopy of anti-5-hydroxymethylcytosine (A), DAPI (B) and merged (C) 
showing nuclear localization in aortic VSMC. Wild type (D) and ApoE knockout (E) aortic 
arch cross section showing distribution of anti-5-hydroxymethylcytosine.  
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Figure 18. Assessment of global DNA hydroxymethylation levels in the aortas of wild 
type and ApoE mice fed normal or high fat diets. 
Assessment of global DNA 5-hydroxymethylcytosine levels in the aortic arch of wild type 
and ApoE knockout mice fed normal or high fat diet. Analysis via 5-hmC ELISA 
(n=8/group).  
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Locus Specific Epigenetic DNA Alterations  
 
 The correlation between genome-wide aberrant expression levels of methylation and 
hydroxymethylation and progression of atherosclerosis may suggest that these mechanisms 
play a role in the development of the disease. To determine the effects of methylation and 
hydroxymethylation in the pathogenesis of atherosclerosis, locus specific levels of 5-
methylcytosine and 5-hydroxymethylcytosine within the promoter and proximal enhancer 
region were tested for in a selection of genes relating to atherosclerosis. A selection of genes 
were tested based on three criteria: 1) An association or link with cardiovascular disease 
through associated studies 2) The presence of CpG island within the promoter or proximal 
enhancer region 3) The ability to make primers for glycosylation-coupled  qPCR and that 
can be enzymatically cleaved by MspI. Within the selection of genes, only a few genes 
showed a significant difference in the level of hydroxymethylation between wild type and 
ApoE groups.  
 
Assessment of IGF-1R Expression in Aortas of Wild Type and ApoE Mice 
 
 Because DNA methylation and hydroxymethylation are major epigenetic 
modifications of the genome, they have the potential to silence and induce gene expression. 
Additionally, because of a relatively low level of 5-hydroxymethylcytosine within the 
genome, changes often result in significant epigenetic control, which result in changes in 
protein expression  (Wossidlo, Nakamura et al. 2011). Of the genes tested for the presence of 
5-hydroxymethylcytosine, IGF-1R had significant differences in ApoE as compared to wild 
type control mice (P-value ≥ 0.05).  Because of these differences in the presence of             
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5-hydroxymethylcytosine, IGF-1R expression was further analyzed both at the level of 
transcription and at the level of protein expression. The expression of IGF-1R in wild type 
and ApoE deficient mice was examined in serial aortic sections by fluorescence microscopy 
and a notable lack of IGF-1R and α-SM-actin immunostains (star) and certain areas of stains 
for IGF-1R (arrow) were observed in the ApoE knockout aortic plaque (Figure 19). 
 IGF-1R expression was further analyzed during a range of 9 months from 3 month to 
one year old wild type and ApoE deficient mice (Figure 20).  A significant decrease in     
IGF-1R expression was seen in ApoE in all age ranges as compared to wild type (P<0.05), 
and ApoE deficient mice showed a decrease that positively correlated with aging. 
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Figure 19. Immunofluorescence microscopy of IGF-1R in wild type and ApoE 
knockout aortas.  
WT and ApoE knockout aortas  immunostained with antibodies against IGF-1R (green) and 
α-SM-actin (red). Nuclear counter-staining (blue) was conducted with DAPI in the same 
sections. Note a lack of IGF-1R and α-SM-actin immunostains (star) and certain areas of 
stains for IGF-1R (arrow) in the ApoE knockout aortic plaque. 
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Figure 20. Expression of IGF-1R protein in wild type and ApoE knockout mice during 
aging. 
Protein expression levels of IGF-1R in (A) wild type and (B) ApoE knockout mice during 
aging. Expression levels assessed by western blot analysis from protein extracted from aortic 
VSMCs from 3, 6, and 12 month old mice.  (n=2/group) 
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Figure 21. Expression of IGF-1R mRNA in wild type and ApoE during aging. 
mRNA expression levels of IGF-1R in wild type and ApoE knockout mice during aging. 
Expression levels assessed by RT-qPCR analysis from RNA extracted from aortic VSMCs 
from 3, 6, and 12 month old mice.  (n=3/group) 
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Assessment of 5-Methylcytosine and 5-Hydroxymethylcytosine Levels in IGF-1R Gene 
Promoter and Surrounding Regions. 
  
 Of the genes tested for the presence of 5-hydroxymethylcytosine, IGF-1R had a 
significant differences (P-value ≥ 0.05). To further analyze the epigenetic changes four loci 
were selected within the proximal enhancer and promoter region and analyzed for the 
presence of 5-methylcytosine and 5-hydroxymethylcytosine (Figure 22). 
 
 
Figure 22. Schematic representation of IGF-1R gene promoter and surrounding 
regions.  
Genetic map of IGF-1R showing four loci tested for of 5-methylcytosine and                       
5-hydroxymethylcytosine by qMethyl and glycosylation-coupled  qPCR. Locations shown 
from transcription start site (TSS) in base pairs above line.  Size of qPCR amplicon and 
number of CpG sites shown below line and in blue boxes. 
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 To verify successful amplification, genomic DNA from wild type mice was treated 
with hydroxymethylcytosine glucosyltransferase and subsequently amplified via PCR. All 
loci treated showed successful amplification by qPCR (Figure 23).  
 
 
 
 
                   
Figure 23. Verification of Glucosylation-Coupled qPCR Products for IGF-1R Loci. 
Verification of glucosylation-coupled qPCR products for IGF-1R loci using wildtype 
genomic DNA treated with hydroxymethylcytosine glucosyltransferase but not digested with 
MspI. 
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Figure 24. DNA methylation and hydroxymethylation in IGF-1R  promoter region.  
Comparison of average DNA methylation and hydroxymethylation within the promoter and 
proximal enhancer region of IGF-1R in wild type and ApoE knockout mice fed normal or 
high fat diets.  
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 All four loci were tested first for differences in 5-hydroxymethylcytosine and 5-
methylcytosine levels (Figure24) . ApoE knockout mice showed a decrease in the amount of 
hydroxymethylation as compared to wild type controls (P<0.01). Addition of a high fat diet 
alone and in combination with the genetic knockout of the ApoE gene caused progressive 
reductions in the amounts of 5-hydroxymethylcytosine as compared to wild-type control 
across all four loci tested  (P<0.05) (Figure 24). Conversely, ApoE mice showed an increase 
in the amount of methylation as compared to wild type controls across all four loci. 
Additionally, ApoE genetic knockout mice with and without the introduction of a high fat 
diet caused increases in the average amount of   5-methylcytosine as compared to wild type 
control (P<0.05). 
 
TET Methylcytosine Dioxygenase Enzymes in Atherosclerosis  
 
 The conversion of the base 5-methylcytosine to 5-hydroxymethylcytosine is 
governed by the Ten-eleven translocation (TET) methylcytosine dioxygenase family of 
enzymes. To determine which member of the TET family may be involved in this 
conversion, mRNA expression of all TET enzymes were analyzed by RT-qPCR in wild type 
mice. Of the enzymes tested TET2 had the highest and only significant level of  expression 
(P<0.001) (Figure 25).  
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Figure 25. Assessment of TET mRNA expression in wild type  mice.  
Assessment of.of TET1,2, and 3 mRNA transcript levels in vascular aortic arch cells of wild 
type mice by RT-qPCR. (n=3/group)   
 
  
*** 
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 TET2, shown to have the highest level of expression, was then analyzed by           
RT-qPCR in wild type and ApoE knockout mice.  A significant decrease in the amount of 
TET2 was observed both in mRNA and protein expression levels by immunoflurescent 
microscopy (Figure 26, 27).  Expression of TET2 mRNA was further shown to be down-
regulated  by the addition of a high fat diet, with ApoE knockout mice fed a high fat diet 
displaying the lowest expression (P<0.01) (Figure 27). 
 
 
 
Figure 26. Immunofluresecence microscopy of TET2 expression in wild type and ApoE 
aortas. 
WT and ApoE knockout aortas  immunostained with antibody against                                  
5-hydroxymethylcytosine (green)  and nuclear counter-stained with DAPI (blue). Note a 
lack of  expression of TET2 in the ApoE knockout aorta. 
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Figure 27. Assessment of TET2 mRNA expression in wild type and ApoE fed normal or 
high fat diets. 
Expression of TET 2 mRNA transcript levels by RT-qPCR in vascular aortic arch cells of 
wild type and ApoE knockout mice fed normal or high fat diets. (n=3/group)   
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mTOR Expression in Atherosclerosis  
 
 Mechanistic target of rapamycin (mTOR) is a master  regulator of cell growth, 
proliferation, motility, survival, protein synthesis, autophagy, and transcription. The complex 
mTORC1 acts as a nutrient/energy/redox sensor and controls protein synthesis, becoming 
active in the presence of increased cellular nutrient, oxygen, and energy levels  (Weichhart 
2012). We therefore assessed the expression of mTORC1 in wild type vascular smooth 
muscle cells (VSMC), as well as cells deficient in the ApoE protein. mTORC1 expression 
was higher in VSMCs deficient in ApoE and showed increases in cellular localization via 
immunoflurescent microscopy (Figure 28).    
 To determine the affect of diet on mTOR, mRNA transcript levels were analyzed in  
wild type and ApoE deficient mice with and without the addition of a high fat diet. As 
expected, both wild type and ApoE mice fed the high fat diet showed significant increases in 
the expression levels of mTOR.  Wild type fed the high fat diet showed an approximately 
four fold increase in mTOR levels (Figure 29). 
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Figure 28. Immunofluresecence microscopy of mTORC1 in wild type and ApoE 
VSMCs.  
Wild type (A) and  ApoE knockout (B) aortic  VSMCs grown in chamber-slides were fixed 
and immunostained  with monoclonal antibody against mTORC1 (green)  and nuclear 
counter-stained with DAPI (blue). Note increased  expression of mTORC1 in the ApoE 
knockout VSMCs. 
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Figure 29. Assessment of mTOR mRNA expression in wild type and ApoE mice fed 
normal or high fat diets.  
Expression of mTOR mRNA transcript levels by RT-qPCR in vascular aortic arch cells of 
wild type and ApoE knockout mice fed normal or high fat diets. (n=8/group) 
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 Rapamycin and torin are inhibitors of the mTOR pathway.  Because our data 
suggested that the induction of the major nutrient sensing and growth pathway, mTOR, 
through diet and genetic knockout of ApoE correlated with reductions in TET2 expression 
we sought to define the effects of inhibition of mTOR on TET2. 
 Rapamycin inhibits mTOR by binding to its  FKBP12 receptor,  the FKBP12 
complex then binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, 
thereby inhibiting its activity (Marx, Jayaraman et al. 1995). As expected, treatment of wild 
type VSMCs with either rapamycin or torin produced a significant decrease in mTOR 
mRNA transcript expression in a time dependent manor (Figure 30).  
 
Figure 30.  Assessment of mTOR in VSMCs treated with Rapamycin 
Rapamycin-induced inhibition of mTOR in VSMCs over a 24 hour period causes a time 
dependent attenuation in mTOR mRNA expression levels by RT-qPCR analysis (n=3/group). 
* 
** 
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Figure 31. Assessment of mTOR in VSMCs treated with Torin. 
Torin-induced inhibition of mTOR in VSMCs over a 24 hour period causes a time dependent 
reduction in mTOR mRNA expression levels by RT-qPCR analysis (n=3/group). 
 
  
** ** 
*** 
77 
Attenuation of TET2 by mTOR  
 
 As previously shown, TET2 expression is negatively regulated via diet and genetic 
induced hyperlipidemia Thus, we next sought to assess the connection between TET2 and 
the mTOR pathway.  To evaluate this pathway's role, VSMCs were treated with the mTOR 
inhibitors rapamycin and torin. After 24 hours treatment with mTOR inhibitor, TET2 levels 
in VSMCs were significantly elevated as compared with control untreated cells (P<0.05) 
(Figure 32). Furthermore, TET2 levels were more highly expressed with the more potent 
mTOR inhibitor, torin, as compared to treatment with rapamycin (P<0,01) (Figure 32).  
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Figure 32.  TET2 expression in VSMC treated with mTOR inhibitor 
In response to inhibition of mTOR by rapamycin and torin, VSMCs treated for 24 hours 
show an increase in TET2 mRNA expression.  
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IGF-1R Expression in Response to Inhibition of mTOR. 
 
 Because rapamycin induces TET2 expression, we next sought to assess the 
connection between IGF-1R and rapamycin/torin-induced inhibition of the mTOR pathway. 
After 24 hours treatment with mTOR inhibitors ,IGF-1R levels in VSMCs were significantly 
elevated as compared with control untreated cells (P<0.05) (Figure 33).  
 
 
 
Figure 33. IGF-1R expression in VSMC treated with mTOR inhibitors. 
Inhibition of mTOR by rapamycin and torin of VSMCs treated for 24 hours show an 
increase in IGF-1R mRNA expression (P<0.05) (n=3/group).  
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Chapter 5: Discussion 
 
 
 
 
The Development of Atherosclerosis in Diet Adjusted and Genetically Modified Mice 
 
 In general, most rodent strains do not develop atherosclerosis as seen in humans and 
large animals (Zadelaar, Kleemann et al. 2007). However, the murine model provides one of 
the most frequently utilized and easily manipulated animal models for the study of 
atherosclerosis. Genetic manipulation through gene knockout and diet manipulation can both 
effectively and relatively quickly generate atherosclerotic plaque formation. We, as well as 
numerous others, have produced a murine model of atherosclerosis utilizing both diet-
induced and genetically modified models. The combination of both diet-induced and/or the 
genetic knockout of the ApoE protein have allowed a wide spectrum of the disease with 
varying degrees of severity of atherosclerosis within the models.  
 To  correlate the  risk factors to epigenetic alterations in atherosclerosis, in this study 
we examined several basic physiological parameters in both wild type and ApoE knockout 
mice, including average body weight, BMI, hypertension, hypercholesterolemia, an 
cardiovascular function.  
 We observed significantly increased body weight and BMI in wild type mice fed a 
high fat diet. Additionally, ApoE knockout mice fed a high fat diet showed a higher average 
increase in weight and BMI. However, no significant difference in weight and BMI was 
found when comparing wild type and ApoE knockout groups without the diet-induced 
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weight gain. This is likely due to the fact that genetic knockout of the ApoE protein causes   
severe hypercholesterolemia with most of the plasma cholesterol within the  VLDL fraction 
(Plump, Smith et al. 1992). However, the absence of ApoE also significantly impairs 
delivery of liver-derived VLDL to adipocytes. In the adipocytes, ApoE interacts with the 
VLDL receptor, which facilitates hydrolysis of triglycerides by lipoprotein lipases. 
Additionally, within the cells of atherosclerotic plaques the inability to secrete ApoE has 
been shown to have an independent proatherogenetic effect (Fazio, Babaev et al. 1997). This 
suggests that hyperlipidemia, whether through diet induction or ApoE knockout, is an 
essential prerequisite for atherosclerosis. However, as our results show, the induction of 
hyperlipidemia may not be associated with weight gain as reported with the ApoE knockout 
weight where the impaired delivery of liver-derived VLDL to adipocytes likely suppresses 
body weight gain and body fat accumulation. 
 Being closely related and a function of body weight, BMI, or body mass index, 
functionally quantifies the amount of tissue mass within the mouse. On normal chow, all 
groups fell within the normal BMI range. However, when subjected to a high fat diet, both 
wild type and ApoE knockout groups showed significant gains in BMI and were categorized 
as obese. Although obesity alone does not fully reveal the extent of atherosclerosis, it 
remains a significant risk factor and factors such as BMI and weight do positively correlate 
with the degree of atherosclerosis independent of other risk factors (Hubert, Feinleib et al. 
1983).  
 Hypertension is a well-established cardiovascular risk factor that independently 
increases the risk of atherosclerosis (Alexander 1995). When subjected to a high fat diet, 
both wild type and ApoE deficient mice showed an increase in both systolic and diastolic 
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blood pressure over those groups fed a normal chow diet. Additionally, wild type mice fed a 
high fat diet showed blood pressure similar to that of ApoE knockout mice. Of the four 
groups, ApoE knockout mice fed a high fat diet showed the highest proclivity for 
hypertension with five of eight mice defined as hypertensive. Although not sufficient when 
taken alone, the elevated blood pressure in groups deficient for ApoE and those fed a high 
fat diet suggest a resulting increase in the amount and severity of atherosclerosis. 
 Ultrasound remains the most frequently used modality for the routine non-invasive 
evaluation of cardiac and vascular function in humans and experimental animals. Here we 
report that the degree of myocardial hypertrophy assessed by transthoracic 
echocardiography, as evidenced by LV wall thickness and IVS measurements,  increased 
with genetic knockout of the ApoE protein. The degree of hypertrophy was further 
intensified with the addition of a high fat diet. We further demonstrate an aortic arch arterial 
wall thickening within the genetic knockout of ApoE that is progressively worsened by the 
addition of a high fat diet. Because of the nature and limitations of transthoracic aortic 
intimal wall evaluations, it is difficult to quantify the severity of atherosclerosis. 
Nevertheless, the morphological and functional characterization via ultrasound is consistent 
with myocardial hypertrophy and cardiovascular dysfunction caused by vascular occlusion 
associated with atherosclerosis. 
 The present study has identified, both qualitatively and quantitatively, intra-
cytoplasmic neutral lipid accumulation within the aorta. En face Oil Red O staining in aortas 
demonstrated minimal lipid-rich atherosclerotic lesions within control wild type mice. 
However, in ApoE knockout mice these lesions become more numerous and larger, 
extending from the aortic outflow through the descending aorta. Overall lipid deposition 
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within the aortic arch increased with the addition of a high fat diet, while microscopic aortic 
ring analysis showed a progressive increase in cellular phenotypic dysfunction. Our data 
reveals an atherosclerotic progression from simple fatty streaks to fibroatheroma, displaying 
multiple lipid cores and fibrotic layers, in a model that is genetic knockout and diet 
inducible.  
 In this study, we generated a model for assessing the progression of atherosclerosis 
utilizing genetic and environmental factors. In vivo assessments of weight, blood pressure, 
echocardiography, and aortic ultrasound, as well as ex vivo examination and quantification 
of tissue reflect the pathophysiology. Our data, taken as a whole, shows  varying degrees of 
severity of atherosclerosis within the models suitable for the assessment of the epigenetic 
contribution of DNA methylation and hydroxymethylation to the disease. 
 
Global DNA Methylation and Hydroxymethylation in Diet Adjusted and Genetically 
Modified Mice Prone to Atherosclerosis. 
 
 There has been increasing experimental and clinical evidence supporting the concept 
that aberrant methylation patterns are present in cancerous and diseased states. Our data 
reveals a positive correlation between genome wide de-methylation and the severity of 
atherosclerosis. Additionally, we found a similar progressive loss in hydroxymethylation 
that was induced by both diet and genetic knockout of ApoE which closely correlated to the 
severity of atherosclerosis as determined by weight, blood pressure, echocardiography, and 
aortic ultrasound, as well as ex vivo examination. These findings suggest that methylation 
and hydroxymethylation could influence the onset and progression of arthrosclerosis 
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because of their capacity to affect gene expression and their alteration in response to genetic 
and environmental influences such as diet. Furthermore, our finding lends itself to further 
investigation of the role of DNA methylation and hydroxymethylation during the 
development of arthrosclerosis. 
 
Locus Specific DNA Methylation and Hydroxymethylation.  
 
 Within the selection of genes tested we report significant differences in the level of 
hydroxymethylation in normal and advanced atherosclerotic tissue. Of the genes tested for 
the presence of 5-hydroxymethylcytosine, IGF-1R showed significant differences during 
atherosclerotic progression, which may be an indication of its sensitivity to, and regulation 
by, epigenetic control. We report the reduction of the mRNA transcript and protein level of 
IGF-1R associated with the severity of atherosclerosis. The correlation between increases in 
epigenetic marks 5-methylcytosine and the decrease in 5-hydroxymethylcytosine along with 
the reduction of IGF-1R through atherogenesis suggest the presence of a  mechanism of 
epigenetic regulation of IGF-1R.  
 
TET Methylcytosine Dioxygenase Family of Enzymes in Atherosclerosis. 
 
 The conversion of the base 5-methylcytosine to 5-hydroxymethylcytosine is 
governed by the TET methylcytosine dioxygenase family of enzymes. Our data reveals 
negligible levels of TET1 and TET3 within the aortic vasculature and VSMCs during 
normal physiology. The presence of both 5-hydroxymethylcytosine and TET2 within the 
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aortic vasculature and VSMCs suggests that TET2 is the sole modulator of this conversion. 
Furthermore, the data reveals that TET2 is attenuated during the onset and progression of 
atherosclerosis. This reduction is positively correlated with the degree of atherosclerosis 
and, additionally, its attenuation is consistent with the reductions in the level of 
hydroxymethylation within the IGF-1R promoter region. The findings that TET2 is the sole 
modulator of this conversion and is affected by the degree of atherosclerosis reveals a novel 
epigenetic regulation of vascular cell signal transduction and proliferation during 
atherosclerosis. It suggests that during normal physiology TET2 plays a role in the 
regulation of the balance between DNA hydroxymethylation and methylation, and to that 
end, activation and inactivation of IGF-1R expression during atherosclerosis.   
 
Potential Targets of Rapamycin (mTOR) for Epigenetics of Atherosclerosis. 
 
 Mechanistic target of rapamycin (mTOR) is a master  regulator of cell growth, 
proliferation, motility, survival, protein synthesis, autophagy, and transcription. The complex 
mTORC1 acts as a nutrient/energy/redox sensor and controls protein synthesis, becoming 
active in the presence of increased cellular nutrient, oxygen, and energy levels  (Weichhart 
2012). Consistent with other reports, we find that mTOR mRNA transcript and protein level 
are up-regulated by the addition of a high fat diet. This increase is also seen within the 
hypercholesterolemic ApoE knockout model, which is further up-regulated within this 
model with the addition of a high fat diet. The mTOR pathway, in addition to its role in 
nutrient sensing, cell growth, and proliferation, has been shown to be a regulator of SMC 
differentiation (Martin, Rzucidlo et al. 2004). Through rapamycin-induced inhibition of the 
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mTOR pathway, our data indicates that TET2 is negatively attenuated by diet induced up-
regulation of mTOR. Moreover, when mTORC1 is inhibited via rapamycin, TET2 levels are 
up-regulated and our data shows downstream levels of 5-hydroxymethylcytosine are 
increased within the promoter of IGF-1R. Accompanying the increased levels of  5-
hydroxymethylcytosine within the promoter region of IGF-1R, we also report the 
reactivation of IGF-1R expression through increases in IGF-1R mRNA transcript levels. 
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Figure 34. Schematic Representation of a Potential Mechanism of IGF-1R Gene 
Regulation Via DNA Hydroxymethylation.  
Atherogenesis induced via genetic knockout of ApoE or diet up-regulates the mTOR 
pathway which in turn negatively regulates TET2. CpG rich loci within IGF-1R have been 
implicated in the binding of TET2 which then catalyzes the conversion of  5-methylcytosine 
to 5-hydroxymethylcytosine, an activator of gene expression.  
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Conclusions  
 
 Previous reports have indicated a link between mTOR and IGF-1 signaling (Johnson, 
Rabinovitch et al. 2013). During normal cell function IGF-1R signaling via insulin receptor 
substrate 1/2 (IRS 1/2) activates the PI3K/AKT pathway. IRS 1/2, through direct and 
indirect down-stream targets, blocks negative cell functions such as oxidative stress, 
apoptosis, pro-inflammatory signaling, and cellular dysfunction while mTOR, through 
activation of the IRS 1/2/PI3K/Akt pathway causes cell growth, survival, and protein 
synthesis. However, mTOR pathway activation via cellular nutrients and energy, as well as, 
IGF-1R signaling changes during overstimulation. Excessive activation of the mTOR/S6K 
pathway creates a negative feedback loop and inactivates IRS1/2, thus causing insulin and 
IGF-1R signaling resistance (Blagosklonny 2013). In this way, IGF-1R exerts its effect on 
mTOR signaling with the possibility of attenuation during excessive activation or 
overstimulation. Our novel finding that vascular cell signal transduction and proliferation 
though IGF-1R can be up-regulated via  rapamycin-induced inhibition of the mTOR 
pathway creates an additional level of regulation via overstimulation of mTOR leading to 
down-regulation of TET2, and thus, down-regulation of IGF-1R via loss of 5-
hydroxymethylcytosine.  
  
89 
 
 
Figure 35. Schematic Representation of the Potential Epigenetic Regulation of  
IGF-1R Expression and Signaling.  
IGF-1Rsignaling via insulin receptor substrate 1/2 (IRS1/2) activates the 
PI3K/Akt/mTOR/S6K pathway. The mTOR/S6K pathway is also activated by nutrients such 
as glucose, TNF and numerous other factors. Excessive activation of mTOR/S6K pathway in 
turn inactivates IRS1/2, thus causing insulin resistance.  
 
 
TET2 
90 
 The mTOR pathway has been a target for many years because of its implication in 
restenosis. Rapamycin has be used within intra arterial stents to prevent arterial intimal 
thickening and numerous studies have shown rapamycin prevents proliferation of not only T 
cells but also proliferation and migration of VSMCs (Mohacsi, Tuller et al. 1997).  Several 
pathways have been implicated for rapamycin's affect including blocking G1/S transition by 
binding to a cytosolic receptor, FK506 binding protein 12. Rapamycin binding to 
FK506BP12 ultimately prevents proliferation by reducing cdk2 activity (Marx, Jayaraman et 
al. 1995). Here we report an additional pathway in which rapamycin/mTOR/TET2 could 
affect VSMC contractility, metabolism, hypertrophy, apoptosis, autophagy, stem cell 
regeneration and senescence through the known effects of IGF-1R function (Ren and 
Anversa 2015). 
 
Further studies 
 
 The novel finding that the normal vascular cell signaling of IGF-1R during 
atherosclerosis can be epigenetically up-regulated via rapamycin-induced inhibition of the 
mTOR pathway leads to the possibility of clinical intervention.  In the case of 
atherosclerosis, the possibility exists of utilizing this pathway to restore normal cellular 
function. An example of which would be the utilization of a combinatory rapamycin and 
TET2 eluting stent which may present a possible novel avenue of investigation to combat 
restenosis and restore normal function.  Further investigation may also lead to advancements 
in oncology. Aberrant IGF-1 signaling is indicated in, and a hallmark of, a host of cancers.  
Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas of childhood and 
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adolescence. RMSs as well as numerous other cancers exploit the IGF-1R pathway. In 
RMSs, rapamycin is frequently used as an anti-proliferative cancer treatment through its 
inhibition of mTOR downstream signaling. Paradoxically, treatment of cancer cells with 
rapamycin activates AKT, due to blockade of the previously mentioned feedback loop via 
(S6K). Through dual treatment of RMS tumors with rapamycin and TET2 inhibitors the 
proliferative IGF-1R signaling cascade may be dramatically reduced. In this way, the 
mTOR/TET2/IGF-1R pathway may become an attractive possible treatment for not only 
RMSs, but other IGF-1R driven cancers and numerous disease conditions in which aberrant 
IGF-1R signaling is indicated 
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